Effect of donor type on volume of blood transfusions required after allogeneic hematopoietic cell transplantation.
ABO Blood-Group System
Adolescent
Adult
Aged
Biomarkers
Blood Grouping and Crossmatching
Blood Transfusion
/ economics
Clinical Decision-Making
Disease Management
Erythrocyte Indices
Female
Hematopoietic Stem Cell Transplantation
/ adverse effects
Humans
Male
Middle Aged
Platelet Count
Postoperative Care
/ economics
Time Factors
Tissue Donors
Transplantation, Homologous
Young Adult
Allogeneic hematopoietic cell transplantation
Blood transfusion
Donor
Platelet
Red blood cell
Transfusion independence
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
30
09
2020
accepted:
17
11
2020
revised:
13
11
2020
pubmed:
5
1
2021
medline:
22
6
2021
entrez:
4
1
2021
Statut:
ppublish
Résumé
We reviewed blood product use in 729 consecutive allogeneic hematopoietic cell transplantation (allo-HCT) recipients at our center to assess the volume of red blood cells (RBCs) and platelets required after allo-HCT. The median number of bags required by day 30 was 4 for RBCs (range 0-22) and 9.5 for platelets (0-53). Multivariate analysis showed that related peripheral blood stem cell transplantation (PBSCT) required a significantly lower RBC transfusion volume by day 30 compared to unrelated bone marrow transplantation (UBMT). PBSCT from haplo-identical related donors and cord blood transplantation (CBT) required a significantly greater RBC transfusion volume. For platelet transfusion, related and unrelated PBSCT required a significantly lower volume than UBMT, and CBT a greater volume. Other factors independently associated with greater RBC transfusion volume were male sex, disease status other than complete remission, and major ABO mismatch. For platelet transfusion, these were male sex, disease status, and HCT-specific comorbidity index of 1. Although the burden of blood transfusions may not be the most important factor when choosing a donor type, our findings may provide a foundation for nationwide strategies to prepare blood products and inform aspects of national healthcare expenditures.
Identifiants
pubmed: 33392973
doi: 10.1007/s12185-020-03041-2
pii: 10.1007/s12185-020-03041-2
doi:
Substances chimiques
ABO Blood-Group System
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
518-529Références
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091–101.
doi: 10.1056/NEJMoa1004383
Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? J Clin Oncol. 2011;29(7):805–13.
doi: 10.1200/JCO.2010.32.5001
Kurosawa S, Yakushijin K, Yamaguchi T, Atsuta Y, Nagamura-Inoue T, Akiyama H, et al. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry. Bone Marrow Transplant. 2013;48(4):529–36.
doi: 10.1038/bmt.2012.172
Tanaka Y, Kurosawa S, Tajima K, Tanaka T, Ito R, Inoue Y, et al. Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51(4):553–9.
doi: 10.1038/bmt.2015.330
Transplantation TJDCfHC (2018) Activities and outcomes of hematopoietic cell transplantation in Japan. http://wwwjdchctorjp/en/data/slide/2018/.
Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175–81.
doi: 10.1056/NEJM200101183440303
Blaise D, Kuentz M, Fortanier C, Bourhis JH, Milpied N, Sutton L, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol. 2000;18(3):537–46.
doi: 10.1200/JCO.2000.18.3.537
Dey BR, Shaffer J, Yee AJ, McAfee S, Caron M, Power K, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. Bone Marrow Transplant. 2007;40(1):19–27.
doi: 10.1038/sj.bmt.1705688
Solh M, Brunstein C, Morgan S, Weisdorf D. Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants. Biol Blood Marrow Transplant. 2011;17(5):710–6.
doi: 10.1016/j.bbmt.2010.08.017
Wang Z, Sorror ML, Leisenring W, Schoch G, Maloney DG, Sandmaier BM, et al. The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. Br J Haematol. 2010;149(1):101–10.
doi: 10.1111/j.1365-2141.2009.08073.x
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A, et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System. Int J Hematol. 2007;86(3):269–74.
doi: 10.1007/BF03006932
Fukuda T, editor (2018) National Cancer Center Hospital Pocket Manual of Stem Cell Traplantation. Tokyo 2018.
Health LaWM. Guidelines for Usage of Blood Products (revised version). 2017.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628–33.
doi: 10.1016/j.bbmt.2009.07.004
Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367–9.
doi: 10.1016/j.bbmt.2008.12.497
Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–93.
doi: 10.1053/j.seminoncol.2012.09.005
Sugita J, Kagaya Y, Miyamoto T, Shibasaki Y, Nagafuji K, Ota S, et al. Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. Bone Marrow Transplant. 2019;54(3):432–41.
doi: 10.1038/s41409-018-0279-1
Sorror ML, Giralt S, Sandmaier BM, De Lima M, Shahjahan M, Maloney DG, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110(13):4606–13.
doi: 10.1182/blood-2007-06-096966
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
doi: 10.1038/bmt.2012.244
Heldal D, Tjonnfjord G, Brinch L, Albrechtsen D, Egeland T, Steen R, et al. A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant. 2000;25(11):1129–36.
doi: 10.1038/sj.bmt.1702422
Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant. 2009;15(5):564–73.
doi: 10.1016/j.bbmt.2009.01.011
Matsuno N, Wake A, Uchida N, Ishiwata K, Araoka H, Takagi S, et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood. 2009;114(8):1689–95.
doi: 10.1182/blood-2008-12-194696
Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016;101(12):1592–602.
doi: 10.3324/haematol.2016.149427
Kurosawa S, Oshima K, Yamaguchi T, Yanagisawa A, Fukuda T, Kanamori H, et al (2017) Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant
Polizzotto MN, Wood EM, Ingham H, Keller AJ. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion. 2008;48(1):55–63.
pubmed: 17894794
Takamatsu J. Transfusion-transmitted viral infection. Japanese J Clin Hematol. 2007;48(10):1422–7.
Okazaki H. Transfusion-related acute lung injury (TRALI) and transfusion-associated circulatory overload (TACO). Japanese J Clin Pathol. 2013;61(5):399–406.
Popovsky MA. Pulmonary consequences of transfusion: TRALI and TACO. Transfusion Apheresis Sci. 2006;34(3):243–4.
doi: 10.1016/j.transci.2006.01.005
Solh M, Morgan S, McCullough J, Shanley R, Weisdorf DJ. Blood transfusions and pulmonary complications after hematopoietic cell transplantation. Transfusion. 2016;56(3):653–61.
doi: 10.1111/trf.13415
Hosoba S, Waller EK, Shenvi N, Graiser M, Easley KA, Al-Kadhimi Z, et al. Peritransplantation red blood cell transfusion is associated with increased risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018;24(5):973–82.
doi: 10.1016/j.bbmt.2018.01.003